Assessment of Liver Fibrosis Stage and Cirrhosis Regression After Long-Term Follow-Up Following Sustained Virological Response
Diagnostics · 15.01.2026 · 16 (2) · 279
DOI: 10.3390/diagnostics16020279 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 15.01.2026. Verfasst von Lidia Canillas und 8 weiteren Autor:innen. Beteiligte Einrichtung: Liver Section, Gastroenterology Department, Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute), Department of Medicine and Life Sci…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Previous studies have demonstrated that the cessation of liver damage after HCV cure can improve liver function, histological necroinflammation, and portal hypertension. However, scarce data about fibrosis stage or cirrhosis regression have been reported during follow-up.
Methods
A prospective study evaluating hepatic biopsies and liver stiffness measurement by vibration-controlled transient elastography (VCTE-LSM) after the end of treatment (EOT) in patients with compensated advanced chronic liver disease (cACLD). Fibrosis was evaluated according to two semi-quantitative grading systems (METAVIR and Laennec) at 6 years after EOT (LB6) and compared with biopsies at 3 years (LB3).
Results
Fifty-four patients with LB6 (34 with paired LB3–LB6) were included. Median (IQR) age was 53.9 (48.5–59.3), 38 (70.4%) were men, and 13 (24.1%) were HIV-coinfected. The VCTE-LSM was >15 kPa in 30 (55.6%). The LB6 (81.4 months after EOT) showed non-advanced fibrosis (F1–F2) in 12 (22.4%) patients, bridging (F3) in 26 (48.2%), and cirrhosis (F4) in 16 (29.6%): F4A in 7 (13.0%), F4B in 4 (7.4%), and F4C in 5 (9.3%). The 1-year post-EOT follow-up VCTE-LSM ≤ 8.6 kPa identifies patients without advanced fibrosis (AUROC = 0.929), with a negative predictive value of 88.9% and a positive predictive value of 95.2%. Paired biopsies showed regression in 9 (47.4%) out of 19 patients with cirrhosis: 8 (61.5%) of 13 with F4A but only 1 (16.7%) of 6 with F4B–F4C.
Conclusions
Advanced fibrosis persists in most patients with advanced chronic liver disease after HCV eradication. Regression is possible in mild cirrhosis. However, it is a limited and slow event.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Liver Section, Gastroenterology Department, Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute), Department of Medicine and Life Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain.
- Department of Gastrointestinal and Hepatobiliary Pathology, Hospital del Mar, 08003 Barcelona, Spain.
- Abdominal Unit, Radiology Department, Hospital del Mar, 08003 Barcelona, Spain.
- Liver Unit, Hospital Clínic, Institut D'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Biomedical Research Net-working Center in Hepatic and Digestive Diseases (CIBEREHD), Universitat de Barcelona, 08036 Barce…
ORCID-Profile: Lidia Canillas, Teresa Broquetas, José A Carrión
Zitieren
APA
Canillas, L., Naranjo, D., Broquetas, T., Sánchez, J., Pocurull, A., Garrido, E., Fernández, R., Forns, X., & Carrión, J. A. (2026). Assessment of Liver Fibrosis Stage and Cirrhosis Regression After Long-Term Follow-Up Following Sustained Virological Response. Diagnostics, 16(2), 279. https://doi.org/10.3390/diagnostics16020279
Vancouver
Canillas L, Naranjo D, Broquetas T, Sánchez J, Pocurull A, Garrido E, et al. Assessment of Liver Fibrosis Stage and Cirrhosis Regression After Long-Term Follow-Up Following Sustained Virological Response. Diagnostics. 2026;16(2):279. doi:10.3390/diagnostics16020279
BibTeX
@article{Canillas2026,
author = {Canillas, Lidia and Naranjo, Dolores and Broquetas, Teresa and Sánchez, Juan and Pocurull, Anna and Garrido, Esther and Fernández, Rosa and Forns, Xavier and Carrión, José A},
title = {Assessment of Liver Fibrosis Stage and Cirrhosis Regression After Long-Term Follow-Up Following Sustained Virological Response},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {2},
pages = {279},
doi = {10.3390/diagnostics16020279}
}
EUVIMED